Commentary: Defining and Managing Suicidal Risk in Patients Taking Psychotropic Medications [CME]
J Clin Psychiatry 2009;70(6):782-789
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
In March 2004, the US Food and Drug Administration (FDA) issued
a public health advisory warning that antidepressant treatment may
increase suicidality and worsen depression in adult and pediatric patients.
Then, in May 2007, the FDA proposed that the black box warning in the
prescribing information for antidepressants and other drugs used to treat depression
be updated to include a warning about an increased risk of suicidality
in young adults. In January 2008, the FDA announced that antiepileptic
medication labeling will be required to include a warning about an
increased risk of suicidality.